These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 16258207

  • 1. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
    Kitagawa M, Tashiro K.
    Intern Med; 2005 Sep; 44(9):939-43. PubMed ID: 16258207
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 4. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ, Yoo HS, Lee HS, Jeong HE, Kim SJ, Oh JS, Kim JS, Sohn YH, Lee PH.
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [Abstract] [Full Text] [Related]

  • 5. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ.
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [Abstract] [Full Text] [Related]

  • 6. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009 May; 109(1):51-4. PubMed ID: 19156087
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G, Liss C, Reines S, Irr J, Nibbelink D.
    Eur Neurol; 1997 May; 37(1):23-7. PubMed ID: 9018028
    [Abstract] [Full Text] [Related]

  • 9. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM.
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [Abstract] [Full Text] [Related]

  • 10. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO study group.
    Lancet; 2013 Nov; 365(9463):947-54. PubMed ID: 15766996
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N.
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
    Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, Johnson R, Chernick D, Hubble J.
    J Parkinsons Dis; 2020 Jan; 10(2):543-558. PubMed ID: 31929122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.